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The distribution of the T29C TGFβ1 gene polymorphism was analyzed in 198 hypertensives with left ventricular hypertrophy
(LVH) and in 235 hypertensives without LVH. Circulating TGFβ1 levels, procollagen type III levels, microalbuminuria, and left
ventricular geometry and function were evaluated in all the hypertensives with LVH subgrouped according to T29C TGFβ1 gene
polymorphism. Circulating TGFβ1 was evaluated by ELISA technique, procollagen type III by a specific radioimmunoassay,
microalbuminuria by radioimmunoassay, and left ventricular geometry and function by echocardiography. All groups were
comparable for gender, age, and sex. Regarding T29C TGFβ1 gene polymorphism, prevalence of TC or CC genotypes was
significantly (P < .05) higher in hypertensives with LVH than hypertensives without LVH TC and CC LVH hypertensives were
characterized by a higher prevalence of subjects with microalbuminuria (P < .05 TC and CC versus TT), by increased levels
of TGFβ1, procollagen type III, urinary albumin excretion, LVM, LVM/h2.7, and lower values of left ventricular ejection fraction
(P < .05 TC and CC versus TT). Our data suggest that T29C TGFβ1 gene polymorphism was associated with clinical characteristics
adequate to recognize a subset of LVH hypertensives with a higher severity of hypertension.
1. Introduction
Hypertension represents the most common powerful risk
factor for cardiovascular morbidity and mortality [1]. High
blood pressure is associated with adverse morphological and
functional changes in the cardiovascular and renal system,
including left ventricular hypertrophy (LVH), microalbu-
minuria and progressive renal and heart disease.
The disproportional accumulation of fibrous tissue is the
major characteristic of the adverse structural remodelling
of cardiac tissue in hypertensives promoting systolic and
diastolic dysfunction [2–5].
Transforming growth factor β1 (TGFβ1) is a multifunc-
tional cytokine and its gene has been found in position
19q13.2, 19q13.1 on chromosome 19 and it has 7 exons and
the length of the whole gene is 17.52 kb.
TGFβ1 overproduction acts on cardiomyocytes as well
as on cardiac fibroblasts inducing cardiac fibrosis and
hypertrophy [6, 7]. In addition, the reduction in circulating
TGFβ1 through a block of the renin-angiotensin system
(RAS) was reported to be associated with an improvement
of renal function and a reversion in LVH [8, 9]. Moreover,
recent experimental data indicate that blockade of the TGFβ,
through a novel orally specific inhibitor of the TGFβ receptor
1, results in significant improvement of deleterious cardiac
remodelling after infarction [10].
Production of TGFβ1 is in part under genetic control
[11]. Eight single nucleotide polymorphism (SNPs) have
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Table 1: Clinical characteristics and distribution of Leu10 →Pro10 genotypes in hypertensives (Ht) with and without left ventricular
hypertrophy (LVH).
Ht with LVH Ht without LVH P=
n. 198 235
Age 50 ± 10 49 ± 10 .300
Gender (F/M) 90/108 124/111 .590
BMI (Kg/m2) 25 ± 6 24 ± 6 .085
WHR 0.86 ± 0.1 0.85 ± 0.1 .300
SBP (mm/Hg) 144 ± 15 143 ± 16 .505
DBP (mm/Hg) 88 ± 9 87 ± 10 .279
MBP (mm/Hg) 106 ± 9 105 ± 9 .250
Ht treated (%) 94.4% (187/198) 94.9% (223/235) .987∗
Diuretics 9% (17/187) 12.1% (27/223) .394∗
ACEi 58.8% (110/187) 61.8% (138/223) .605∗
ARB 42.8% (80/187) 40.3% (90/223) .607∗
CaCB 11.8% (22/187) 17.3% (30/223) .199∗
Duration of treatment (yrs) 6.5 ± 3.3 6.2 ± 3.9 .393
T29C (Leu10 →Pro)
TT 15.1% (30/198) 30.6% (72/235) .0418
TC 64.7%∗ (128/198) 49.8% (117/235) .0434
CC 20.2%∗ (40/198) 19.6% (46/235) .0472
TC + CC 84.9% 69.4% .0466
∗z test.
F: Female; M: Male; BMI: Body mass index; WHR: Waist hip ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure;
MBP: mean blood pressure. ACEi: angiotensin converting enzyme inhibitors; ARB: Angiotensin receptor blockers; CaCB: calcium channel blockers. n.s. = not
significant.
been described in TGFβ1 gene and related to its production
and to hypertension and cardiovascular disease [11, 12]. Two
SNPs are located at positions 29 and 74 of the translated
sequence of TGFβ1 and give rise to amino acid substitutions
at positions 10 (Leu10 → Pro) and 25 (Arg25 → Pro)
in the signal peptide of TGFβ1, respectively [12, 13]. The
T29C was reported to influence steady-state concentrations
of TGFβ1 mRNA in peripheral blood mononuclear cells
and serum levels of TGFβ1, and the G74C was found to be
related to TGFβ1 production in peripheral blood leukocytes
[13, 14]. In addition, the Arg25 allele was associated with
risk of hypertension in the normotensives [12, 15] and
with myocardial infarction [12, 16] compared to the Pro25
allele. On the contrary, no studies have been addressed
the evaluation of the role of T29 → C polymorphism of
TGFβ1 gene on left ventricular geometry and function in
hypertensive patients [14, 16].
The aim of this study was to investigate the relationship
between T29C TGFβ1 gene polymorphism (rs1800470),
LVH and clinical severity of hypertension.
In particular, circulating TGFβ1, procollagen type III
levels, microalbuminuria, left ventricular geometry and
function were evaluated in hypertensive patients and related
to genotype profile.
2. Materials and Methods
2.1. Patients. Subjects eligible for the study were screened at
the antihypertensive center of the Department of Internal
Medicine, University of Palermo (Italy). The study pop-
ulation consisted of hypertensive subjects with age ≤65
years. Each patient gave a written consent after received
a detailed description of study procedure. The study was
approved by Ethics Committee of our Institution. Subjects
under antihypertensive treatment or with a casual blood
pressure (SBP) ≥140 mmHg and/or with casual diastolic
blood pressure (DBP) ≥90 mmHg obtained with a standard
sphygmomanometer after 5 minute of rest at three indepen-
dent occasions with patients sitting were considered hyper-
tensives. Exclusion criteria included secondary hypertension,
endocrinal disease and diabetes mellitus, cardiovascular
diseases (defined as myocardial infarction and recent stroke
within previous 6 months, heart failure), severe chronic renal
failure, alcoholism and psychiatric problems.
433 hypertensive subjects fulfilled the inclusion criteria
and they were grouped according to the presence or absence
of LVH, following standard echocardiographic criteria. In
particular all the hypertensives with LVM/h2.7 ≥50 g/m2.7for
men and≥47 g/m2.7for women were considered to have LVH
[19]. Accordingly, 198 hypertensives with LVH and 235 with-
out LVH were recognized and studied. In addition 94.4%
(187/198 pts) of LVH hypertensives and 94.9% (223/235 pts)
of no-LVH hypertensives were under antihypertensive treat-
ment at the beginning of the study. The percent of anti-
hypertensive drugs utilized, such as duration of treatment,
was not significantly diﬀerent in all hypertensive groups
(Table 1), also when subgrouped according to T/C genotypes
(Table 2).
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Table 2: Distribution of clinical measurements in the hypertensives with left ventricular hypertrophy subgrouped according to Leu10 →
Pro10 TGFβ1 genotypes∗.
TT n. 30 TC n. 128 CC n. 40
Gender(F/M) 16/14 60/68 14/26
Age 55 ± 10 50 ± 9 50 ± 9
Weight (Kg) 69 ± 11 72 ± 10 70 ± 9
Height (m) 1.67 ± 0.1 1.65 ± 0.1 1.68 ± 0.1
BMI (Kg/m2) 24 ± 2 25 ± 2 24 ± 3
WHR 0.85 ± 0.1 0.87 ± 0.1 0.87± 0.1
SBP (mmHg) 143 ± 16 146 ± 16 141 ± 16
DBP (mmHg) 87 ± 10 90 ± 11 89 ± 8
MBP (mmHg) 105 ± 11 108 ± 11 106 ± 9
Antihypertensive drugs
Diuretics 3/30 (10%) 10/128 (7.9%) 4/40 (10%)
ACEi 16/30 (53.4%) 75/128 (58.6%) 19/40 (47.5%)
ARB 12/30 (40%) 58/128 (42.1%) 14/40 (35%)
CaCB 4/30 (13.3%) 12/128 (8.4%) 6/40 (15%)
F: Female; M: Male; BMI: Body mass index; WHR: waist hip ratio; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MBP: Mean blood pressure;
ACEi: angiotensin converting enzyme inhibitors; ARB: Angiotensin receptor blockers; CaCB: calcium channel blockers.
∗All variables were not significantly diﬀerent among the groups.
2.2. DNA Isolation and Genotyping. Genotyping was per-
formed by investigators blinded to clinical status.
Peripheral venous blood was collected in EDTA from all
the patients and stored at −70◦C.
The PCR approach was used to analyze SNP in the coding
regions of TGFβ1.
The study of the TGBβ1 polymorphism was done by
analyzing the sequence. The polymorphism is on exon 1 at
+869 from the beginning of the transcription and generate
an amino acid substitution in position 10 (Leu → Pro). This
study analyzed the genotypes derived from this substitutions.
PCR was performed on purified DNA obtained using the
GenElute Blood Genomic Dna Kit by Sigma: which provided
sequence-specific oligonucleotide primers
T869C:
Forward 5′-TTCCCTCGAGGCCCTCCTA -3′
Reverse 5′-GCCGCAGCTTGGACAGGAT-3′
Briefly, PCR reactions were carried out in a total
volume of 50-μL containing approximately 5 μL of genomic
DNA(0.1 μg/μL), 2μL of forward and reverse primers
(100 ng/μL), 5 μL of 10 × reaction buﬀer (160 mM
(NH4)2SO4, 670 mM Tris-HCl (pH 8,8 at 25◦C), 15 mM
MgCl2, 0, 1% Tween 20), 4μL of 2 mM dNTPs (invitrogen),
4 μL of DMSO, 0, 1u of Taq Polymerase.
Amplification was carried out in a Robocycler using
cycle parameters of 3 minutes and 30 seconds at 95◦C
(initial denaturation), 35 cycles of 95◦C for 45 seconds
(denaturation), 62◦C for 30 seconds (primer annealing) and
a final extension for 10 minutes at 72◦C.
T869C: the PCR generated amplicons with a fragment
size of 294 Bp.
All PCR products were resolved on 2% agarose gel with
3 μL of ethidium bromide (Figure 1).
1 2 3 4 Marker
300 BP
250 BP
294 BP
50 BP
Figure 1: 2% agar gel for confirming the amplification fragment
(294 Bp). Subject 1–4, M marker 50 Bp (invitrogen).
2.3. Sequencing. PCR products were sequenced to genotype
in all the subjects. PCR reactions in 50 μL were directly
sequenced by MWG (the full name is Eurofins MWG
Operon, see http://www.eurofinsdna.com/home.html) and
from sequence electropherograms was analysed the pres-
ence of single-nucleotide polymorphisms T869C in all the
subjects (Figure 2). The distribution of SNP TGFβ1 gene
between both hypertensive groups were reported in Table 1.
2.4. Biochemical Measurements. Patients underwent a gen-
eral analytical laboratory parameters profile including BUN,
creatinine and clearance, glycaemia, electrolytes (serum
sodium, potassium, chloride), cholesterol by routine labora-
tory methods.
Peripheral venous blood was obtained from each patient
and the sera were isolated and stored at−70◦C. TGF β1 levels
were determined by using a solid-phase specific sandwich
ELISA technique (R&D Systems, Inc. Minneapolis, USA)
as previously described [17]. The interassay and intra-
assay variations for determining TGFβ1 were 8% and 6%,
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TGCGCCCTTCTCCCTGAGGACCTCAGCTTTCCCTCGAGGCCCTCCTACCTTTTGCCGGGAGACCCCCAGCCCCTG
CAGGGGCGGGGCCTCCCCACCACACCAGCCCTGTTCGCGCTCTCGGCAGTGCCGGGGGGCGCCGCCTCCCCCAT
GCCGCCCTCCGGGCTGCGGCTGCTGCC/TGCTGCTGCTACCGCTGCTGTGGCTACTGGTGCTGACGCCTGGCCGG
CCGGCCGCGGGACTATCCACCTGCAAGACTATCGACATGGAGCTGGTGAAGCGGAAGCGCATCGAGGCCATCC
GCGGCCAGATCCTGTCCAAGCTGCGGCTCGCCAGC
Figure 2: Localization scheme of the polymorphism at +869 C/T, situated inside exon 1, positions of the forward and reverse primers of the
294 Bp fragment are indicated.
respectively. The sensitivity, hence minum level of detection
of TGFβ1 by sandwich ELISA, was 5 pg/mL.
To determine amino-terminal PIIIP, blood samples
were taken from each patient and stored at 40◦C until
manipulation. PIIIP were determined by using a specific
radioimmunoassay (Orion Diagnostic Finland), as previ-
ously described [18]. The sensitivity of PIIIP was 1 ng/mL,
the intra-assay variations ranged from 1.7% to 4.3% and
interassay variations from 3.2% to 5.3%.
2.5. Urinary Albumin Excretion (UAE). To eliminate the
intra-individual day-to-day variability of UAE, three con-
secutive 24-hour urine collections were used. In addition,
to assess the completeness of a 24 hours urine collection,
measurements of urinary rate of clearance of creatinine
were evaluated. UAE was measured by radioimmuno-assay
(limit of detection, 0.1 mg/dL; Inter-assay coeﬃcient 3.5%).
Microalbuminuric patients were defined as a level of UAE
≥20 and <300 mg/24 hours.
2.6. Echocardiographic Measurements. All patients under-
went an echocardiography examination M and B-mode,
by a computerized echocardiography (ESAOTE, Italy) for
the determination of following parameters: left ventricu-
lar telediastolic internal diameter (LVIDd), interventricular
septum (IVSTd), and posterior wall thickness (PWTd).
The Penn convention was used to calculate left ventricular
mass (LVM). LVM was normalized for height to the 2.7
power [19]. The relative wall thickness (RWT) by formula
[(PWTd/LVIDd) × 2] was also calculated. Ejection fraction
from left ventricular end-diastolic and end-systolic volumes
was measured from the apical four chamber view, using
the ellipsoidal single-plane algorithm. Mean ejection frac-
tion was automatically calculated by the echocardiographic
processing system. In our laboratory the ejection fraction
calculated over five consecutive beats permitted optimal
reproducibility and accuracy [20].
LV relaxation and filling were evaluated by pulsed-wave
Doppler interrogation of the LV inflow tract from the apical
four-chamber view, with the sample volume placed at the tips
of the mitral valve. After a stable signal of the transmitral
flow velocity was obtained, the Doppler cursor was moved
toward the LV outflow tract in the apical five-chamber view
for recording both mitral and aortic signals, including the
closing click of the aortic valve and the opening click of the
mitral valve. Doppler signals were recorded at high speed
(80–120 mm/s) with the subjects in held expiration. An
average of five beats was used for analysis.
Isovolumic relaxation time (IVRT) was calculated as the
time from the closure click of the aortic valve to the opening
click of the mitral valve. When either the closing or opening
click was not identified, the time from the end of the aortic
flow to the onset of mitral flow from the continuous wave
interrogation of the LV inflow-outflow tract was used. Peak
early transmitral flow velocity (E), peak late transmitral flow
velocity (A), and the deceleration time of E velocity (DTE)
were measured at the tips of mitral leaflets at the maximum
amplitude of E velocity. DTE was measured as the time from
peak E velocity to the time when E wave descent intercept the
zero line.
2.7. Statistical Analysis. No sample size was calculated for the
lack of any information about the main goal of the study.
Continuous variables are reported as mean ± SD. Abso-
lute and relative frequencies are reported when appropriate.
For continuous variables, comparisons among groups were
performed by Kruskall-Wallis test as non parametric analysis
of variance. Multiple pairwise comparisons were made by
the Critchlow-Fligner method. Contingency tables were
analyzed by the Q2 test or the Fisher exact test when possible.
Pairwise comparison between frequencies were made by Z-
test after Chi-square statistical significant value. A two tailed
P value <.05 was considered significant.
Logistic regression analysis, according to Hosmer and
Lemeshow method [21] has been used to investigate asso-
ciation between TT or TC plus CC genotypes and both
laboratory and clinical measurements. Continuous variables
were put into the model as quintiles.
3. Results
The results of the study are presented in Tables 1–5.
3.1. Distribution of T29C TGFβ1 Genotypes in Hypertensives
With and Without LVH. The distribution of T29C genotypes
in both hypertensive groups has been reported in Table 1.
The prevalence of TC (P = .0434), and TC plus CC (P =
.0466) genotypes, was significantly higher in hypertensives
with LVH than hypertensives without LVH (64.7% versus
49.8%, and 84.9% versus 61.4%, respectively).
Genotype frequency distribution in the two groups
of hypertensives occurred according to Hardy-Weinberg
proportions.
Since genotype frequency distribution was not significant
diﬀerent in hypertensives without LVH, only hypertensives
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with LVH were further subdivided into three groups, accord-
ing to T/C genotypes.
3.2. Distribution of Clinical Characteristics in Hypertensives
With LVH Subgrouped According to T29C TGFβ1 Genotypes.
The association between genotypes and clinical character-
istics in the three groups of hypertensives with LVH have
been reported in Table 2. All the groups were homogeneous
regarding to age, BMI, WHR and blood pressure. LVH
hypertensives with TC or CC genotype were characterized
by a significant higher prevalence of subjects with microal-
buminuria (P < .05 TC and CC versus TT).
No significant diﬀerence in the prevalence and duration
of antihypertensive drugs utilized was observed among the
groups (Tables 1 and 2). In addition no significant diﬀerence
also in statin administration was observed among the groups.
3.3. Circulating TGFβ1, Type III Collagen, Urinary Albu-
min Excretion and Echocardiographic Parameters. Urinary
albumin excretion, circulating TGFβ1, PIIIP, LVM and
LVM/h2.7levels were significantly (P < .05) higher and left
ventricular ejection fraction values were significantly (P <
.05) lower in LVH hypertensives with TC or CC genotype
than those detectable in LVH hypertensives homozygous for
allele T (Tables 3 and 4).
4. Logistic Regression Analysis
This analysis indicated an association between higher levels
of PIIIP and TC or CC genotypes, even if adjusted for
LVM/h2.7 and urinary albumin excretion values (Table 5).
5. Discussion and Conclusion
To our knowledge this is the first study to investigate the
impact of TGFβ1 Leu → Pro at codon 10 polymorphism
(rs1800470) on left ventricular geometry and function in
hypertensive patients. Our data indicate a higher prevalence
of TC and CC Leu10 →Pro polymorphism in hypertensives
with LVH than hypertensives without LVH, associated to
some unfavorable clinical characteristics of hypertension. In
fact, LVH hypertensive subjects with TC or CC genotype
were characterized by a higher prevalence of subjects with
microalbuminuria, higher value of LVM and lower left
ventricular ejection fraction. In our opinion, this association
doesn’t reflect unknown diﬀerences in population ancestry
between the two hypertensive groups. We consider the prob-
ability of false positive inference attributable to population
studied rather small because the two hypertensive groups
were recruited from an ethnically homogenous population.
In this context recent results from Xu et al. [22] revealed
a genetic association of TGFβ1 + 915 Arg → Pro at codon
25 polymorphism with LVH in a Chinese hypertensive
population, while the codon 10 genotypes did not show any
association to LVH. Even if in this study we have analyzed
only TGFβ1 Leu → Pro at codon 10 polymorphism, our
recent unpublished data indicated no association between
TGFβ1 + 915 Arg → Pro at codon 25 polymorphism
Table 3: Renal measurements, Circulating TGFβ1 and Pro-collagen
III in hypertensives with left ventricular hypertrophy subgrouped
according to Leu10 → Pro10 TGFβ1 genotypes.
TT n. 30 TC n. 128 CC n. 40
BUN (mg/dL) 39 ± 6 38 ± 7 39 ± 8
Creatinine (μmol/L) 61.9 ±17.7 79.6 ± 17.7 79.6 ± 17.7
Clearance (mL/min) 108 ± 30 103 ± 38 102 ± 32
UAE (mg/24h) 51 ± 40 113 ± 36∗ 92 ± 69∗
Microalbuminuric 5/30 80/128 21/40
pts (%) (16.7%) (62.5%)∗ (52.5%)∗
TGFβ1 (ng/mL) 45 ± 22 60 ± 15∗ 58 ± 11∗
PIIIP (U/L) 0.60 ± 0.1 0.71 ± 0.1∗ 0.65 ± 0.1∗
BUN: Blood urea nitrogen; TGFβ1: Transforming growth factor β1; PIIIP:
amino-terminal propeptide of type III procollagen; UAE: Urinary albumin
excretion; pts: patients.
∗P < .05 versus TT.
Table 4: Left ventricular geometry and function in hypertensives
with left ventricular hypertrophy subgrouped according to Leu10 →
Pro10 TGFβ1 genotypes.
TT n. 30 TC n. 128 CC n. 40
LVIDd (mm) 49 ± 3 48 ± 4 48 ± 5
IVSTd (mm) 11 ± 1 11.9 ± 2 11,8 ± 2
PWTd (mm) 9.6 ± 1 10.5 ± 2 10.6 ± 1
RWT 0.39 ± 0.1 0.44 ± 0.1 0.44 ± 0.1
LVM (gr) 197 ± 33 228 ± 40∗ 216 ± 55∗
LVM/h2.7 (gr/h2.7) 53 ± 8 59 ± 10∗ 56 ± 9∗
EF % 63 ± 3 57 ± 2∗ 56 ± 3∗
E/A 1.5 ± 0.4 1.4 ± 0.3 1.4 ± 0.4
DTE (ms) 202 ± 38 204 ± 42 205 ± 44
IVRT (ms) 80 ± 12 78 ± 15 81 ± 14
LVIDd: Left ventricular telediastolic internal diameter; IVSTd: Interven-
tricular septum thickness; PWTd: Posterior wall thickness; LVM: Left
ventricular mass; LVM/h2.7: Left ventricular mass indexed 2.7; RWT:
Relative wall thickness; EF: Ejection fraction; E/A: Peak early transmitral
flow/peak late transmitral flow; DTE: E deceleration time; IVRT: Isovolumic
relaxation time.
∗P < .05 versus TT.
and hypertension in a Caucasian hypertensive population.
These contrasting data may be explained by ethnicity of
two hypertensive populations considered (Caucasian and
Chinese).
Although changes in the heart caused by hypertension
are well known, the eﬀective mechanisms are not entirely
clarified. Despite the role of hemodynamic eﬀects and
growth factors have been largely reported, other metabolic
and inflammatory factors have to be also considered [23].
Literature data and the results of our previous stud-
ies indicate an overproduction of circulating TGFβ1 in
hypertensives. Moreover, hypertensives with target organ
damage (TOD) have higher circulating levels of TGFβ1
than hypertensives without TOD. This finding seems to
attribute an important role to TGFβ1 overproduction in the
pathophysiology of essential hypertension and its sequelae
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Table 5: Logistic regression analysis. Deviance (likelihood ratio) chi-
square = 14,281753 df = 3 P = .0025.
Independent variable O.R∗ P=
PIIIP 8.1 (C.I: 1.50–15.20) .0466
UAE 4.3 (C.I: 0.93–8.43) .0814
LVM/h2.7 2.58 (C.I: 0.57–4.34) .203
logit y = −0,142938 + 2,090717 PIIIP+1,461049 UAE+0,949264 LVM/h2.7.
logit y = 1 for TC + CC genotypes.
logit y = 0 for TT genotype.
O.R.= odd ratio; C.I = Confidence interval.
∗Odd ratio is referred to quintile variation of each variable.
[24, 25]. The TGFβ1 overproduction in hypertension may
be explained by the eﬀects of various factors, such as
elevated angiotensin II, increased fluid shear stress and a
diﬀerential expression of TGFβ1 linked to DNA polymor-
phisms in the promoter [11]. Plasma concentrations of active
and also of acid-activable TGFβ1 is predominantly under
genetic control (heritability estimate 0.54). Up regulation
of TGFβ1 system in monocytes of hypertensive patients
and association of TGFβ1 gene polymorphism with risk of
hypertension suggests that quantitative diﬀerence in TGFβ1
production may determine the intensity of the process
of vascular remodelling and therefore influence overall
susceptibility to the development of hypertension [26]. On
the other hand experimental data indicate that abnormalities
in responsiveness to TGFβ1 overproduction, as evidenced
by collagen formation, may represent a pathophysiological
molecular mechanism in hypertension [27, 28]. The results
from ECTIM study [12] suggest that TGFβ1 Arg25-Pro
polymorphism might be associated with hypertension but
does not address the issue of quantitative phenotypes related
to TGFβ1 production in relation to hypertension. On the
contrary no study has been addressed the evaluation of the
role of Leu-to-Pro polymorphism at codon 10 to explain
whether the substitution has functional and biological
importance, or it could aﬀect protein transport. In view
of this we have now shown that the serum concentration
of TGFβ1 was significantly diﬀerent in LVH hypertensives
subgrouped according to T29 → C polymorphism. It is
possible that the T29 → C polymorphism of the TGFβ1 gene
is linked to some other genes that are actually responsible for
the development of hypertension.
Moreover, the significant change in circulating TGFβ1
values among LVH hypertensive groups indicated that TC or
CC genotypes could be able to induce quantitative change in
the production of the cytokine and it might aﬀect also the
function of signal peptide, perhaps influencing intracellular
traﬃcking or export eﬃciency of preprotein [15].
In addition, our data suggest some clinical consider-
ations. First, LVH hypertensive subjects with TC or CC
genotypes were characterized by a higher value of microalbu-
minuria, LVM and by a systolic left ventricular dysfunction.
This might indicate that hypertension in these subjects
has to be considered more severe. Another aspect of our
study that seems to be interesting is related to the higher
collagen production in LVH hypertensive subjects with TC
or CC genotype than in those homozygous for allele T.
This finding is further supported by analysis of logistic
regression indicating that PIIIP may be considered the most
important marker associated to T and C alleles. In fact,
analysis of odd ratio indicates that the risk of association
with T or C allele increases eight fold for each PIIIP quintile
variation. In our opinion this finding might further support
our previous results [5, 23] indicating that overproduction
in circulating TGFβ1 may contribute to the progression of
renal and cardiovascular damage in obese and/or hyperten-
sive subjects. In particular, the present study emphasizes
the unfavourable eﬀects of TGFβ1 overproduction on left
ventricular geometry and function that might be mediated
by an higher collagen production [5, 24, 29]. In view of
this the association of TC or CC with a higher clinical
severity of hypertension seems to indicate that TGFβ1 is a
susceptibility locus for hypertension. A potential limit of this
study was to have computed no a priori evaluation of the β
error and consequently the power of our statistical analysis.
However this involves considerations only about the sample
size. Accordingly the negative results of our study has needed
further evaluations.
In conclusion our data are attractive to indicate that LVH
hypertensive subjects with TC or CC genotypes (Leu10 →
Pro polymorphism, rs 1800470) might be considered a
particular subset of LVH hypertensives with a more sever-
ity of hypertension. However, the present results require
verifications in other populations, since it is well known
that hypertension is under the control of many genes that
contribute modest individual eﬀects, and TGFβ1 may act in
concert with other hypertension susceptibility loci.
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